Literature DB >> 11123102

The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide.

S J Oliver1.   

Abstract

The immunity generated in response to an antigenic stimulus can result in at least two distinct subclasses of immune responses, commonly referred to as Th1 and Th2. This review describes Th1- and Th2-type immune responses in animal models and in human mediated disease. Evidence obtained from working within these models suggests that manipulating the Th1/Th2 balance in the immune response can alter disease processes. The possible application of this strategy in scleroderma is presented. The immune modulating effects of the drug thalidomide on Th1 and Th2 immunity are also described, along with the drug's potential application to disease processes like scleroderma.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11123102     DOI： 10.1007/s11926-000-0025-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


  67 in total

1.  Direct contact between T lymphocytes and human dermal fibroblasts or synoviocytes down-regulates types I and III collagen production via cell-associated cytokines.

Authors:  R Rezzonico; D Burger; J M Dayer
Journal:  J Biol Chem       Date:  1998-07-24       Impact factor: 5.157

2.  Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease.

Authors:  R Giacomelli; P Cipriani; R Lattanzio; M Di Franco; M Locanto; I Parzanese; A Passacantando; A Ciocci; G Tonietti
Journal:  Clin Exp Immunol       Date:  1997-04       Impact factor: 4.330

3.  Scleroderma-like changes due to chronic graft-versus-host disease.

Authors:  R A Graham-Brown; I Sarkany
Journal:  Clin Exp Dermatol       Date:  1983-09       Impact factor: 3.470

4.  Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

Authors:  J M Jacobson; J S Greenspan; J Spritzler; N Ketter; J L Fahey; J B Jackson; L Fox; M Chernoff; A W Wu; L A MacPhail; G J Vasquez; D A Wohl
Journal:  N Engl J Med       Date:  1997-05-22       Impact factor: 91.245

Review 5.  Pathophysiology of the inflammatory response.

Authors:  D S Pearlman
Journal:  J Allergy Clin Immunol       Date:  1999-10       Impact factor: 10.793

6.  Leukocytes of patients with Schistosoma mansoni respond with a Th2 pattern of cytokine production to mitogen or egg antigens but with a Th0 pattern to worm antigens.

Authors:  M E Williams; S Montenegro; A L Domingues; T A Wynn; K Teixeira; S Mahanty; A Coutinho; A Sher
Journal:  J Infect Dis       Date:  1994-10       Impact factor: 5.226

7.  Differential production of interferon-gamma and interleukin-4 in response to Th1- and Th2-stimulating pathogens by gamma delta T cells in vivo.

Authors:  D A Ferrick; M D Schrenzel; T Mulvania; B Hsieh; W G Ferlin; H Lepper
Journal:  Nature       Date:  1995-01-19       Impact factor: 49.962

8.  Interferon-alpha and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture.

Authors:  V M Kähäri; J Heino; T Vuorio; E Vuorio
Journal:  Biochim Biophys Acta       Date:  1988-01-18

9.  Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.

Authors:  P A Haslett; L G Corral; M Albert; G Kaplan
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307

10.  Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells.

Authors:  R Fernandez-Botran; V M Sanders; T R Mosmann; E S Vitetta
Journal:  J Exp Med       Date:  1988-08-01       Impact factor: 14.307
View more
  6 in total

Review 1.  Properties of thalidomide and its analogues: implications for anticancer therapy.

Authors:  Steven K Teo
Journal:  AAPS J       Date:  2005-03-22       Impact factor: 4.009

2.  Telangiectasis in CREST syndrome and systemic sclerosis: correlation of clinical and pathological features with response to pulsed dye laser treatment.

Authors:  Shlomit Halachmi; Osama Gabari; Sarit Cohen; Romelia Koren; Dan Ben Amitai; Moshe Lapidoth
Journal:  Lasers Med Sci       Date:  2013-03-14       Impact factor: 3.161

3.  The prevalence of systemic sclerosis is increased among patients with alopecia areata: a population-based study.

Authors:  Khalaf Kridin; Dana Tzur Bitan; Doron Comaneshter; Arnon D Cohen
Journal:  Immunol Res       Date:  2019-10       Impact factor: 2.829

4.  U-Scores for Multivariate Data in Sports.

Authors:  Knut M Wittkowski; Tingting Song; Kent Anderson; John E Daniels
Journal:  J Quant Anal Sports       Date:  2008-07-18

5.  The use of streptolysin o for the treatment of scars, adhesions and fibrosis: initial investigations using murine models of scleroderma.

Authors:  Stephen W Mamber; Vit Long; Ryan G Rhodes; Sunthorn Pond-Tor; Lyn R Wheeler; Kellie Fredericks; Brian Vanscoy; Jean-Frederic Sauniere; Remy Steinschneider; Jean-Claude Laurent; John McMichael
Journal:  Nonlinearity Biol Toxicol Med       Date:  2004-04

Review 6.  Reconstitution of the immune system and clinical correlates after stem cell transplantation for systemic sclerosis.

Authors:  Marianna Y Kawashima-Vasconcelos; Maynara Santana-Gonçalves; Djúlio C Zanin-Silva; Kelen C R Malmegrim; Maria Carolina Oliveira
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.